Status:
COMPLETED
Presence or Absence of Blood in the GI Lumen
Lead Sponsor:
NYU Langone Health
Conditions:
Upper GI Bleeding
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Bleedings in the upper digestive tract are common. Usually, laboratory and clinical parameters are considered to establish a suspicion for a bleeding in the digestive tract and to estimate urgency of ...
Detailed Description
The purpose of the study was to access safety and accuracy of Hemopill and its receiver. Patients scheduled for endoscopy on the basis of suspected UGIB are generally eligible for inclusion into the t...
Eligibility Criteria
Inclusion
- Patient is scheduled for endoscopy due to suspicion of UGIB based on clinical and / or laboratory findings
- Signed informed consent
- Age ≥ 18 years
- Willingness and ability to participate in the study procedure
Exclusion
- Contraindications to the use of the HemoPill acute, such as:
- Known gastrointestinal obstruction, stricture, fistula, or diverticula
- Dysphagia or other swallowing disorders
- Pregnancy
- Incapacity to provide informed consent
- In patients with cardiac pacemakers and other implanted medical devices
Key Trial Info
Start Date :
June 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 22 2024
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05415124
Start Date
June 17 2022
End Date
October 22 2024
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Health
New York, New York, United States, 10016